Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.
Article
CAS
PubMed
Google Scholar
DeVita VT Jr, Chu E. A history of Cancer chemotherapy. Cancer Res. 2008;68(21):8643–53.
Article
CAS
PubMed
Google Scholar
Chan WL, Lam KO, Siu WK, Yuen KK. Chemotherapy at end-of-life: an integration of oncology and palliative team. Support Care Cancer. 2016;24(3):1421–7.
Article
PubMed
Google Scholar
Roeland EJ, LeBlanc TW. Palliative chemotherapy: oxymoron or misunderstanding? BMC Palliat Care. 2016;15(1):33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Reljic T, et al. Treatment targeted at underying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open. 2017;7:e014661.
Article
PubMed
PubMed Central
Google Scholar
Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.
Article
PubMed
Google Scholar
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015;1(6):778–84.
Article
PubMed
PubMed Central
Google Scholar
Crosara Teixeira M, Marques DF, Ferrari AC, Alves MF, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clin Colorectal Cancer. 2015;14(1):52–7.
Article
PubMed
Google Scholar
Ali M, Cripps MC, Balchin K, Spencer J, Wheatley-Price P. Palliative inpatient chemotherapy: clinical benefit or harm? J Clin Oncol. 2012;30(15_suppl):e19527.
Google Scholar
Rocque GB, Barnett AE, Illig LC, Eickhoff JC, Bailey HH, Campbell TC, Stewart JA, Cleary JF. Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care? J Oncol Pract. 2013;9(1):51–4.
Article
PubMed
Google Scholar
Rocha LS, Riechelmann RP. Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. Clinics. 2018;73(suppl 1):e542s.
Lee HS, Chun KH, Moon D, Lee S, Lee S. Trends in receiving chemotherapy for advanced cancer patients at the end of life. BMC Palliat Care. 2015;14(1):4.
Article
PubMed
PubMed Central
Google Scholar
Soto-Perez-de-Celis E, Chavarri-Guerra Y, Pastrana T, Ruiz-Mendoza R, Bukowski A, Goss PE. End-of-life Care in Latin America. J Glob Oncol. 2017;3(3):261–70.
Article
PubMed
Google Scholar
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
Article
CAS
PubMed
Google Scholar
Schouwenburg MG, Jochems A, Leeneman B, Franken MG, Van Den Eertwegh AJ, Haanen JB, Van Zeijl MC, Aarts MJ, Van Akkooi AC, Van Den Berkmortel FW, Blokx WA. Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Res. 2018;28(4):326–32.
CAS
PubMed
Google Scholar
Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;59(2):367–74.
Article
Google Scholar
Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37–41.
Article
CAS
PubMed
Google Scholar
Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 study group. Semin Oncol. 1999;26(1 Suppl 5):6–12.
CAS
PubMed
Google Scholar
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–103.
Article
CAS
PubMed
Google Scholar
Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30.
Article
PubMed
Google Scholar
Sánchez-Muñoz A, Pérez-Ruiz E, Sáez MI, Trigo JM, Galindo MM, Manzaneque L, Jiménez B, Muros B, Alba E. Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clin Transl Oncol. 2011;13(6):426–9.
Article
PubMed
Google Scholar
Wheatley-Price P, Ali M, Balchin K, Spencer J, Fitzgibbon E, Cripps C. The role of palliative chemotherapy in hospitalized patients. Curr Oncol. 2014;21(4):187–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24(21):3490–6.
Article
PubMed
Google Scholar
Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of Cancer care near the end of life. J Clin Oncol. 2004;22:315–21.
Article
PubMed
Google Scholar
Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. Bmj. 2014;348:g1219.
Article
PubMed
PubMed Central
Google Scholar
Cheon S, Agarwal A, Popovic M, Milakovic M, Lam M, Fu W, DiGiovanni J, Lam H, Lechner B, Pulenzas N, et al. The accuracy of clinicians' predictions of survival in advanced cancer: a review. Ann Palliat Med. 2016;5(1):22–9.
PubMed
Google Scholar
Su C, Zhou F, Shen J, Zhao J, O'Brien M. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced non-small cell lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - still a daily challenge. Eur J Cancer. 2017;83:266–78.
Article
CAS
PubMed
Google Scholar
Rochigneux P, Raoul JL, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, Morin L. Use of chemotherapy near the end of life: what factors matter. Ann Oncol. 2017;28(4):809–17.
CAS
PubMed
Google Scholar
Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA, Peppercorn JM, Phillips T, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96–112.
Article
PubMed
Google Scholar
Braga S. Why do our patients get chemotherapy until the end of life? Ann Oncol. 2011;22(11):2345–8.
Article
CAS
PubMed
Google Scholar
Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138:639–43.
Article
PubMed
Google Scholar
Hashimoto K, Yonemori K, Katsumata N, Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M, Fujiwara Y. Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist. 2009;14(7):752–9.
Article
PubMed
Google Scholar
Caires-Lima R, Cayres K, Protásio B, Caires I, Andrade J, Rocha L, Takahashi TK, Hoff PM, de Castro G, Mak MP. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. Ecancermedicalscience. 2018;12:831.
Article
PubMed
PubMed Central
Google Scholar
Simmons CPL, McMillan DC, McWilliams K, Sande TA, Fearon KC, Tuck S, Fallon MT, Laird BJ. Prognostic Tools in Patients With Advanced Cancer: A Systematic Review. J Pain Symptom Manag. 2017;53(5):962–970.e910.
Article
Google Scholar
Pembrolizumab in patients with non-small cell lung Cancer and a performance status 2 (PeePS2) [https://clinicaltrials.gov/ct2/show/NCT02733159].
A study of Atezolizumab compared with chemotherapy in treatment Naïve participants with locally advanced or recurrent or metastatic non-small cell lung Cancer who are deemed unsuitable for platinum-containing therapy (IPSOS) [https://clinicaltrials.gov/ct2/show/NCT03191786].
Matsuo N, Sekine A, Kato T, Hosoda C, Ito H, Baba T, Umeda S, Iwasawa T, Okudela K, Ogura T. Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review. Intern Med. 2016;55(5):507–9.
Article
CAS
PubMed
Google Scholar
Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, et al. The Globalization of Cooperative Groups. Semin Oncol. 2015;42(5):693–712.
Article
PubMed
PubMed Central
Google Scholar
Grössmann N, Del Paggio JC, Wolf S, Sullivan R, Booth CM, Rosian K, Emprechtinger R, Wild C. Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit. Eur J Cancer. 2017;82:66–71.
Article
PubMed
Google Scholar